ArticleJournal of diabetes investigation2026
USP18 mediates high glucose-induced cardiomyocyte injury by regulating the JAK/STAT signaling pathway through stabilizing FOXC2 expression.
Article in Journal of diabetes investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Diabetic cardiomyopathy as a disorder of proteostatic maladaptation: context-dependent ubiquitin-specific protease networks.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCardiomyopathy is one of the complications of diabetes, among which myocardial fibrosis is the most typical feature. Ubiquitin-specific peptidase 18 (USP18) is a deubiquitinating enzyme. Multiple studies suggest that it may have the potential to protect against myocardial injury under diabetes, but the specific mechanism remains unclear.
methodsThe high glucose (HG) was used to treat neonatal mouse ventricular myocytes (NMVMs) to induce diabetic myocardial injury models, and gene expression was detected by quantitative reverse transcription polymerase chain reaction (RT-qPCR) and Western blot. The phenotypes of NMVMs were measured using cell counting kit-8 (CCK-8), the corresponding kits, flow cytometry, enzyme-linked immunosorbent assay (ELISA), and DCFH-DA probe. Besides, cell fibrosis was reflected by immunofluorescence (IF) and Western blot assay. Ubiquitination analysis and Cycloheximide (CHX) experiment were applied to assess protein ubiquitination and degradation, respectively.
resultsUSP18 was downregulated in HG-induced NMVMs, and USP18 overexpression promoted viability and inhibited apoptosis of NMVMs exposed to HG. Meanwhile, the inflammation, oxidative stress, and fibrosis of NMVMs impelled by HG were reversed after USP18 upregulation. Mechanically, USP18 stabilized forkhead box C2 (FOXC2) expression by reducing its ubiquitination to participate in regulating NMVM viability, apoptosis, inflammation, oxidative stress, and fibrosis via the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway.
conclusionsUSP18 inhibits the ubiquitination of FOXC2 to stabilize its expression, thereby mediating HG-induced myocardial injury through the JAK/STAT pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.